Does the use of Rabezac L lead to increased risk of fractures?
Nov 4, 2023
Does the use of Rabezac L lead to increased risk of fractures?
Multiple studies conducted in adults have indicated a potential link between the administration of Rabezac L and an elevated risk of fractures related to osteoporosis These fractures commonly occur in the hip wrist or spine The likelihood of experiencing such fractures was found to be higher among patients who were subjected to high doses of this medication It is important to note that high doses refer to the intake of multiple daily doses over a prolonged period typically lasting for a year or more This information emphasizes the necessity for cautious consideration when prescribing Rabezac L to individuals particularly those at an increased risk for osteoporosisrelated fractures While the precise mechanism behind the increased fracture risk is yet to be fully elucidated these findings underline the importance of carefully evaluating the potential benefits versus the potential risks before initiating treatment with Rabezac L Healthcare professionals should exercise caution and take into account individual patient factors such as age sex medical history and concurrent medications in order to minimize any potential harm It is crucial to discuss the potential risks and benefits of Rabezac L with patients ensuring they are wellinformed regarding the potential fracture risk associated with this medication Regular monitoring of bone health including bone mineral density assessments may also be considered in patients requiring longterm treatment with Rabezac L in order to promptly identify any signs of developing osteoporosis and mitigate the risk of fractures